Fig. 7: CAFs reduced BCa sensitivity to cisplatin by stimulating IGF-1/ERβ/Bcl-2 signalling in vivo. | Cell Death & Disease

Fig. 7: CAFs reduced BCa sensitivity to cisplatin by stimulating IGF-1/ERβ/Bcl-2 signalling in vivo.

From: Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling

Fig. 7

a Grouping and intervention schemes. b Changes in the tumour volumes of each group in the verification and intervention study. Tumour volumes were calculated as described in the Materials and methods section. Arrows represent the start of cisplatin treatment, n = 5 per group. The mice were sacrificed after completion of the treatments. c, d Quantification of the tumour sizes in each group in the verification and intervention studies after mice were sacrificed. e The percent reduction of tumour burden was calculated to evaluate the effect of cisplatin treatment as follows: percent reduction of tumour burden = (no treatment group – treatment group)/ no treatment group × 100%. f IHC staining for α-SMA, ERβ and Bcl-2 in xenograft bladder tumour tissues (α-SMA, 200×; ERβ and Bcl-2, 100×) in each group. g Double fluorescence staining of α-SMA (green) and IGF-1 (red) in xenograft bladder tumour tissues (400×). Data are presented as the mean ± SD. *P < 0.05

Back to article page